ARUK 2018 | Targeting proteostasis for the treatment of neurodegenerative diseases

Aggregated misfolded proteins are a common feature of neurogenerative diseases, and are thought to be responsible for many of the symptoms shown by patients. Here, John Skidmore, BA, DPhil, from the Alzheimer’s Research UK (ARUK) Cambridge Drug Discovery Institute, Cambridge, UK, explains how his institute is investigating the manipulation of the proteostatic mechanisms controlling the levels of these misfolded proteins. Dr Skidmore discusses the ways in which this process can be altered and the specific therapeutic targeting of autophagy via the PI5P4 kinases, with hopes to move this work into animal models rapidly. This video was recorded at the ARUK Conference 2018, held in London, UK.